Literature DB >> 9243354

Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis.

K Vadiei1, S Troy, J Korth-Bradley, S T Chiang, J J Zimmerman.   

Abstract

The disposition of amiodarone, an antiarrhythmic agent was evaluated after a single intravenous infusion (5 mg/kg over 15 minutes) in patients of various ages and with various degrees of renal function and left ventricular function. The plasma concentration-time data were obtained from three clinical studies with similar protocols. The data were analyzed by nonlinear mixed-effects modeling (NONMEM) to estimate the population pharmacokinetic parameters of amiodarone and to determine the significant demographic covariates affecting these parameters. The pharmacokinetic parameters of amiodarone (weight-corrected) also were calculated using two-stage analysis and were compared with the results obtained from the mixed-effects analysis. The population plasma concentration-time profile of amiodarone was best described by a four-compartment model. Demographic covariates (i.e., creatinine clearance and ejection fraction) did not improve the final pharmacostatistical model significantly. The results from the two-stage analysis showed no significant relationship between amiodarone pharmacokinetic parameters and age, gender, renal function, or ejection fraction. The results from one study, however, demonstrated that advanced age (> or = 65 years) resulted in reduced amiodarone clearance coupled with a prolonged elimination half-life. No such correlation was detected with NONMEM analysis, which may be partly attributable to the small number of elderly patients. Overall, the results from NONMEM analysis validated the results obtained from the two-stage analysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243354     DOI: 10.1002/j.1552-4604.1997.tb04343.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects.

Authors:  Tsuyoshi Shiga; Takanori Tanaka; Shin Irie; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2010-10-30       Impact factor: 2.037

3.  Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards.

Authors:  Sabin S Egger; Andrea Bachmann; Nathalie Hubmann; Raymond G Schlienger; Stephan Krähenbühl
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 5.  Cardiovascular drug therapy in the elderly: theoretical and practical considerations.

Authors:  Bradley R Williams; Jiwon Kim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

7.  A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.

Authors:  Samantha H Dallefeld; Andrew M Atz; Ram Yogev; Janice E Sullivan; Amira Al-Uzri; Susan R Mendley; Matthew Laughon; Christoph P Hornik; Chiara Melloni; Barrie Harper; Andrew Lewandowski; Jeff Mitchell; Huali Wu; Thomas P Green; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-12       Impact factor: 2.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.